Table 2.
Impacts of 24 weeks therapies of DMARDs on urinary PGIM, TXBM, 12-HETE and LTE4
| PGIM | TXBM | 12-HETE | LTE4 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 0 | Week 24 | Pa | Day 0 | Week 24 | Pa | Day 0 | Week 24 | Pb | Day 0 | Week 24 | Pb | |
| Total | 25.66% | 40.79% | 0.069 | 43.42% | 69.74% | 0.056 | 67.53.% | 72.73% | 0.419 | 23.38% | 28.57% | 0.669 |
| ACT | 28.95% | 50.00% | 0.172 | 65.79% | 76.32% | 0.723 | 63.16% | 78.95% | 0.098 | 23.68% | 26.32% | 0.904 |
| CZP | 19.05% | 30.95% | 0.320 | 16.67% | 61.90% | < 0.001 | Not measured | |||||
| ABA | 38.46% | 51.28% | 0.194 | 66.67% | 82.05% | 0.131 | 71.79% | 66.67% | 0.653 | 23.08% | 30.77% | 0.588 |
| TCZ | 15.15% | 30.30% | 0.218 | 24.24% | 57.58% | 0.019 | Not measured | |||||
ACT, Active Conventional Therapy arm; CZP, Certolizumab Pegol arm; ABA, Abatacept arm; TCZ, Tocilizumab arm; PGIM, 2,3-dinor-6-keto-PGF1α; TXBM, 2,3-dinor-TXB2, 12-HETE, 12-Hydroxyeicosatetraenoic Acid; LTE4, Leukotriene E4; GEE, Generalized Estimating Equations
P values were obtained from the following statistical tests:
aGEE model adjusted for use of NSAIDs and creatinine concentrations
bGEE model adjusted for creatinine concentrations